Posted by Michael Wonder on 24 Feb 2026
Dupixent (dupilumab) approved in the US as the first and only medicine for allergic fungal rhinosinusitis
24 February 2026 - Regeneron Pharmaceuticals and Sanofi today announced that the US FDA has approved Dupixent (dupilumab) for the treatment of adult and paediatric patients aged 6 years and older with allergic fungal rhinosinusitis who have a history of sino-nasal surgery.
The FDA evaluated Dupixent under priority review for the treatment of allergic fungal rhinosinusitis, which is reserved for medicines that have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions.
This approval expands our approved indications in sino-nasal diseases to now include allergic fungal rhinosinusitis, alongside chronic rhinosinusitis with nasal polyps.
